These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10969182)

  • 1. Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function.
    Richards SM; Murphy WJ
    J Neuroimmunol; 2000 Sep; 109(1):56-62. PubMed ID: 10969182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of recombinant human prolactin for treatment of poor puerperal lactation in a rat model.
    Yoneda N; Irahara M; Saito S; Uemura H; Aono T
    Eur J Endocrinol; 1995 Nov; 133(5):613-7. PubMed ID: 7581993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of neuroendocrine hormones to promote reconstitution after bone marrow transplantation.
    Woody MA; Welniak LA; Richards S; Taub DD; Tian Z; Sun R; Longo DL; Murphy WJ
    Neuroimmunomodulation; 1999; 6(1-2):69-80. PubMed ID: 9876237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of growth hormone and prolactin on hematopoiesis.
    Welniak LA; Tian ZG; Sun R; Keller JR; Richards S; Ruscetti FW; Murphy WJ
    Leuk Lymphoma; 2000 Aug; 38(5-6):435-45. PubMed ID: 10953965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of hematopoietic myeloid and megakaryocyte toxicity associated with zidovudine in vivo in mice with recombinant GM-CSF.
    Gallicchio VS; Hughes NK; Tse KF
    Growth Regul; 1994 Jun; 4(2):41-7. PubMed ID: 7950902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactin is an antagonist of TGF-beta activity and promotes proliferation of murine B cell hybridomas.
    Richards SM; Garman RD; Keyes L; Kavanagh B; McPherson JM
    Cell Immunol; 1998 Mar; 184(2):85-91. PubMed ID: 9630834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematopoietic functions in mice: in vitro toxicity to precursor cells and microstromal environment.
    Luster MI; Germolec DR; White KL; Fuchs BA; Fort MM; Tomaszewski JE; Thompson M; Blair PC; McCay JA; Munson AE
    Toxicol Appl Pharmacol; 1989 Nov; 101(2):328-39. PubMed ID: 2554533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.
    Langenheim JF; Chen WY
    Breast Cancer Res Treat; 2005 Apr; 90(3):281-93. PubMed ID: 15830142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of prolactin on hematopoiesis.
    Welniak LA; Richards SM; Murphy WJ
    Lupus; 2001; 10(10):700-5. PubMed ID: 11721696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohematopoietic modulation by oral β-1,3-glucan in mice infected with Listeria monocytogenes.
    Torello CO; de Souza Queiroz J; Oliveira SC; Queiroz ML
    Int Immunopharmacol; 2010 Dec; 10(12):1573-9. PubMed ID: 20951668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R.
    Chen NY; Holle L; Li W; Peirce SK; Beck MT; Chen WY
    Int J Oncol; 2002 Apr; 20(4):813-8. PubMed ID: 11894130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen.
    Tare NS; Bowen S; Warrier RR; Carvajal DM; Benjamin WR; Riley JH; Anderson TD; Gately MK
    J Interferon Cytokine Res; 1995 Apr; 15(4):377-83. PubMed ID: 7627813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of cell shape, adhesion, and lipid accumulation in human breast cancer cells (T-47D) by human prolactin and growth hormone.
    Shiu RP; Paterson JA
    Cancer Res; 1984 Mar; 44(3):1178-86. PubMed ID: 6692402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin regulates antitumor immune response through induction of tumoricidal macrophages and release of IL-12.
    Majumder B; Biswas R; Chattopadhyay U
    Int J Cancer; 2002 Feb; 97(4):493-500. PubMed ID: 11802212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis.
    Clapp C; Martial JA; Guzman RC; Rentier-Delure F; Weiner RI
    Endocrinology; 1993 Sep; 133(3):1292-9. PubMed ID: 7689950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physico-chemical and biological characterizations of two human prolactin analogs exhibiting controversial bioactivity, synthesized in Chinese hamster ovary (CHO) cells.
    Soares CR; Glezer A; Okazaki K; Ueda EK; Heller SR; Walker AM; Goffin V; Bartolini P
    Protein Expr Purif; 2006 Aug; 48(2):182-94. PubMed ID: 16814566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different elements of mini-helix 1 are required for human growth hormone or prolactin action via the prolactin receptor.
    Peterson FC; Brooks CL
    Protein Eng Des Sel; 2004 May; 17(5):417-24. PubMed ID: 15252206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo.
    Sun R; Wei H; Zhang J; Li A; Zhang W; Tian Z
    Neuroimmunomodulation; 2002-2003; 10(3):169-76. PubMed ID: 12481157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High production and optimization of the method for obtaining pure recombinant human prolactin.
    Affonso R; Soares CR; Ribela MT; Bartolini P
    Protein Expr Purif; 2018 Dec; 152():131-136. PubMed ID: 30076885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice.
    Funakoshi S; Taub DD; Anver MR; Raziuddin A; Asai O; Reddy V; Rager H; Fanslow WC; Longo DL; Murphy WJ
    J Clin Invest; 1997 Feb; 99(3):484-91. PubMed ID: 9022082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.